Urethral Bulking Agents in the Treatment of Stress Urinary Incontinence
https://doi.org/10.25207/1608-6228-2019-26-4-84-93
Abstract
Aim. The article presents information on modern urethral bulking agents used in the treatment of female stress urinary incontinence (SUI).
Materials and methods. The authors reviewed the current scientifi c literature on the topic (original articles, monographs, meta-analyses), whose relevance lies in the increasing interest of both clinicians and patients in the minimally invasive treatment of SUI.
Results. On the basis of available information on the use of urethral bulking agents, regulatory bodies prohibited the use of substances that did not meet the requirements of safety and effi cacy. Substances approved for clinical use are safe and show considerable effect, which makes them a suitable alternative to the surgical treatment of SUI.
Conclusions. This kind of treatment is characterised by a low rate of serious complications and a suffi ciently high level of patients’ satisfaction with the results, despite its lower objective cure rate. Further research in this area involves a search for the “ideal” urethral bulking agent, as well as the use of cell technologies.
About the Authors
V. F. Bezhenar
Pavlov First Saint Petersburg State Medical University, Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Vitaly F. Bezhenar — Dr. Sci. (Med.), Prof., Head of the Department for Obstetrics, Gynaecology and Neonatology; Head of the Obstetrics and Gynaecology Clinic
Lva Tolstogo str., 6–8, Saint-Petersburg, 197022
B. V. Arakelyan
Pavlov First Saint Petersburg State Medical University, Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Byuzand V. Arakelyan — Dr. Sci. (Med.), Prof., Department for Obstetrics, Gynaecology and Neonatology; Deputy Head, Obstetrics and Gynaecology Clinic
Lva Tolstogo str., 6–8, Saint-Petersburg, 197022
V. A. Krutova
Kuban State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Victoria A. Krutova — Dr. Sci. (Med.), Ass. Prof., Prorector for Medical Work and Postgraduate Education, Head Doctor, Clinic
Mitrofana Sedina str., 4, Krasnodar, 350063
O. V. Tarabanova
Kuban State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Olga V. Tarabanova — Cand. Sci. (Med.), obstetriciangynaecologist, Gynaecological Department, Clinic
Rozovaya str., 13, Krasnodar, 350078
A. A. Khachetsukova
Kuban State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Aminat A. Khachetsukova — obstetrician-gynaecologist, Gynaecological Department
Mitrofana Sedina str., 4, Krasnodar, 350063
A. S. Turlak
Pavlov First Saint Petersburg State Medical University, Ministry of Healthcare of Russian Federation
Russian Federation
Russian Federation
Anastasia S. Turlak — 5th-year student, Faculty of Medicine
Lva Tolstogo str., 6–8, Saint-Petersburg, 197022
References
1. Abrams P., Andersson K.E., Apostolidis A., Birder L., Bliss D., Brubaker L., Cardozo L., Castro-Diaz D., O’Connell P.R., Cottenden A., Cotterill N., de Ridder D., Dmochowski R., Dumoulin C., Fader M., Fry C., Goldman H., Hanno P., Homma Y., Khullar V., Maher C., Milsom I., Newman D., Nijman R.J.M.,Rademakers K., Robinson D., Rosier P., Rovner E., Salvatore S., Takeda M., Wagg A., Wagner T., Wein A. Recommendations of the International Scientifi c Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse and fecal incontinence. Report of the International Scientifi c Committee. Neurourol. Urodyn. 2018; 37(7): 2271–2272. DOI: 10.1002/nau.23551
2. Pushkar’ D.Yu., Kasyan G.R. Oshibki i oslozhneniya v uroginekologii [Errors and complications in urogynecology]. Moscow: GEOTAR-Media; 2017; 384 (In Russ.)
3. Faiena I., Patel N., Parihar J. S., Calabrese M., Tunuguntla H. Conservative management of urinary incontinence in women. Rev. Urol. 2015; 17(3): 129– 139.
4. Food and Drug Administration, HHS. Obstetrical and gynecological devices; reclassifi cation of surgical mesh for transvaginal pelvic organ prolapse repair. Fed. Regist. 2016; 81: 353–361.
5. Robinson D., Anders K., Cardozo L., Bidmead J., Dixon A., James Balmforth J., Rufford J. What do women want?: Interpretation of the concept of cure. J. Pelv. Мed. Surg. 2003; 9(6): 273–277. DOI: 10.1097/01.spv.0000095060.05452.3f
6. Reynolds W.S., Dmochowski R.R. Urethral bulking: a urology perspective. Urol. Clin. North Am. 2012; 39(3): 279–287. DOI: 10.1016/j.ucl.2012.05.002
7. Mohr S., Siegenthaler M., Mueller M.D., Kuhn A. Bulking agents: an analysis of 500 cases and review of the literature. Int. Urogynecol. J. 2013; 24(2): 241–247. DOI: 10.1007/s00192-012-1834-8
8. Apolikhina I.A., Saidova A.S., Makhmedzhanova F.N. Use of volume-forming drugs to treat female stress urinary incontinence. Akusherstvo i Ginekologiya. 2011; 7–1: 21–24 (In Russ., English abstract).
9. Blaivas J.G., Simma-Chiang V., Gul Z., Dayan L., Kalkan S., Daniel M. Surgery for stress urinary incontinence: autologous fascial sling. Urol. Clin. North Am. 2019; 46(1): 41–52. DOI: 10.1016/j.ucl.2018.08.014
10. Oremus M., Tarride J.E. An economic evaluation of surgery versus collagen injection for the treatment of female stress urinary incontinence. Can. J. Urol. 2010; 17(2): 5087–5093.
11. Wu I., Nahas Z., Kimmerling K. A., Rosson G. D., Elisseeff, J. H. An injectable adipose matrix for soft-tissue reconstruction. Plast. Reconstr. Surg. 2012; 129(6): 1247–1257. DOI: 10.1097/PRS.0b013e31824ec3dc
12. Ghoniem G., Boctor N. Update on urethral bulking agents for female stress urinary incontinence due to intrinsic sphincter defi ciency. J. Urol. Res. 2014; 1(2): 1009.
13. Ghoniem G.M., Miller C.J. A systematic review and meta-analysis ofMacroplastique for treating female stress urinary incontinence. Int. Urogynecol. J. 2013; 24(1): 27–36. DOI: 10.1007/s00192-012-1825-9
14. Zajda J., Farag F. Urolastic — A new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. Adv. Urol. 2013; Article ID 724082, 5 p. DOI: 10.1155/2013/724082
15. de Vries A.M., van Breda H.M.K., Fernandes J.G., Venema P.L.,Heesakkers J.P.F.A. Para-urethral injections with Urolastic® for treatment of female stress urinary incontinence: subjective improvement and safety. Urol. Int. 2017; 99(1): 91–97. DOI: 10.1159/000452450
16. Lightner D.J., Knoedler J.J., Linder B.J. Periurethral bulking agent injection in the treatment of female stress urinary incontinence. In: Goldman H.B., editor. Complications of female incontinence and pelvic reconstructive surgery. Springer International Publishing AG; 2017. 297–305. DOI: 10.1007/978-3-319-498553_27
17. Taşkinlar H., Avlan D., Bahadir G.B., Delibaş A., Nayci A. The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylatepolyalcohol copolymer) in the treatment of primary vesico-ureteral refl ux. Int. Braz. J. Urol. 2016; 42(3): 514–520. DOI: 10.1590/S1677-5538.IBJU.2015.0274
18. Matsuoka P.K., Locali R.F., Pacetta A.M.,Baracat E.C., Haddad J.M. The effi cacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review. Clinics. (Sao Paulo). 2016; 71(2): 94– 100. DOI: 10.6061/clinics/2016(02)08
19. de Vries A.M., Heesakkers J.P.F.A. Contemporary diagnostics and treatment options for female stress urinary incontinence. Asian. J. Urol. 2018; 5(3):141–148. DOI: 10.1016/j.ajur.2017.09.001
20. Kasi A.D., Pergialiotis V., Perrea D.N., Khunda A., Doumouchtsis S.K. Polyacrylamide hydrogel (Bulkamid®) for stress urinary incontinence in women: a systematic review of the literature. Int. Urogynecol. J. 2016; 27(3): 367–375. DOI: 10.1007/s00192-015-2781-y
21. Toozs-Hobson P., Al-Singary W., Fynes M.,Tegerstedt G.,Lose G. Two-year follow-up of an open-label multicenter study of polyacrylamide hydrogel (Bulkamid ®) for female stress and stress-predominant mixed incontinence. Int. Urogynecol. J. 2012; 23(10): 1373–1378. DOI: 10.1007/s00192-012-1761-8
22. Sokol E.R., Karram M.M., Dmochowski R. Effi cacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J. Urol. 2014; 192(3): 843–849. DOI: 10.1016/j.juro.2014.03.109
23. Krhut J., Martan A., Jurakova M., Nemec D., Masata J., Zvara P. Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up. Int. Urogynecol. J. 2016; 27(2): 301–305. DOI: 10.1007/s00192-0152834-2
24. Lightner D.J., Fox J., Klingele C.Cystoscopic injections of dextranomerhyaluronic acid into proximal urethra for urethral incompetence: effi cacy and adverse outcomes. Urology. 2010; 75(6): 1310–1314. DOI: 10.1016/j.urology.2009.12.061
25. Khalef J.A., IbraheemJ.Kh., Zghair L.F. Urodex injection (urethral bulking agent) outcomes intreatment of stress incontinence, interventional study. IOSR J. Pharm. Biol. Sci. 2018; 13(5): 42–45. DOI: 10.9790/3
26. Zangone M.A., Olmedo T., Olea M. Transurethral bulking agent injection in female stress urinaryincontinence: long term results using Opsys®. Pelviperineology. 2012; 31(3): 92–95.
27. Davis N.F., Kheradmand F., Creagh T. Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. Int. Urogynecol. J. 2013; 24(6): 913–919. DOI: 10.1007/s00192-012-2011-9
28. Maggiore L.R.M.U, Bogani G., Meschia M., Sorice P., Braga A, Salvatore S., Ghezzi F., Serati M. Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 189: 48–54. DOI: 10.1016/j.ejogrb.2015.03.025
29. Kuhn A., Stadlmayr W., Lengsfeld D., Mueller M.D. Where should bulking agents for female urodynamic stress incontinence be injected? Int. Urogynecol. J. Pelvic. Floor. Dysfunct. 2008; 19(6): 817–821. DOI: 10.1007/s00192-007-0535-1
30. Klarskov N., Lose G. Urethral pressure refl ectometry and pressure profi lometry in healthy volunteers and stress urinary incontinent women. Neurourol. Urodyn. 2008; 27(8): 807–812. DOI: 10.1002/nau.20617
31. Gill B.C., Firoozi F., Rackley R.R., Talavera F., Kim E.D., Schwartz B.F. Injectable bulking agents for incontinence. 2018; https://emedicine.medscape.com/article/447068-overview (date of the application 16.04.2019).
32. Siddiqui Z.A., Abboudi H., Crawford R., Shah S.Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review. Int. Urogynecol. J. 2017; 28(9): 1275–1284. DOI: 10.1007/s00192-017-3278-7
33. Zhou S., Zhang K., Atala A., Khoury O., Murphy S.V., Zhao W., Fu Q. Stem cell therapy for treatment of stress urinary incontinence: the current status and challenges. Stem. Cells Int. 2016; Article ID 7060975, 7 p. DOI: 10.1155/2016/7060975
Review
For citations:
Bezhenar V.F., Arakelyan B.V., Krutova V.A., Tarabanova O.V., Khachetsukova A.A., Turlak A.S. Urethral Bulking Agents in the Treatment of Stress Urinary Incontinence. Kuban Scientific Medical Bulletin. 2019;26(4):84-93. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-4-84-93
Views:
901
Email this article 